Pharmacological P2X7 receptor inhibition is strongly considered as a therapeutic approach in AD, mainly because its critical role on NLRP3-induced IL-1β release by microglia (Biber et al., 2019). This evidence concerns the gene P2RX7 and Alzheimer disease.